AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in three therapy areas: Oncology; Cardiovascular, Renal & Metabolism; and Respiratory. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.

AstraZeneca is the maker of FluMist® Quadrivalent (Influenza Vaccine Live, Intranasal), an intranasal vaccine for active immunization of persons 2-49 years of age for the prevention of influenza disease caused by influenza A subtype viruses and type B viruses contained in the vaccine. It is also known as LAIV (Live Attenuated Intranasal Vaccine).

For information regarding influenza, ordering, dosing and administration of FluMist® Quadrivalent, and recommendations from the AAP and ACIP, visit here.

For reimbursement support services for FluMist® Quadrivalent, visit here.

FluMist® Quadrivalent is contraindicated in persons who have had a severe allergic reaction (eg, anaphylaxis) to any vaccine component, including egg protein, or after a previous dose of any influenza vaccine, and in children and adolescents receiving concomitant aspirin or aspirin-containing therapy. Most common side effects reported were runny nose or nasal congestion, sore throat, and fever >100°F. For additional Important Safety Information and full Prescribing Information, visit here.

References:
1. Grohskopf LA, Alyanak E, Broder KR, et al. Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices — United States, 2019-20 influenza season. MMWR. 2019;68:1–21.
2. AAP News. No flu vaccine preference for 2019-’20 season. https://www.aapublications.org/news. Accessed 11/7/19.

FLUMIST is a registered trademark of the AstraZeneca group of companies.
©2019 AstraZeneca. All rights reserved. US-34627 Last Updated 12/19